Remote ischaemic preconditioning - translating cardiovascular benefits to humans

Area of Science:

• Cardiology
• Vascular Biology
• Physiology

Background:

• Remote ischaemic preconditioning (RIPC) involves limb ischemia/reperfusion to protect against cardiac and vascular injury.
• Animal studies show RIPC reduces infarct size, but human clinical trials yield inconsistent results.
• Factors like age, fitness, and disease state may affect RIPC efficacy in humans.

Purpose of the Study:

• To review experimental findings on RIPC mechanisms and clinical benefits in humans.
• To elucidate the role of timing and frequency of RIPC in human vascular function.
• To explore RIPC's potential as a preclinical intervention for cardiovascular disease.

Main Methods:

• Review of recent experimental findings in peripheral circulation.
• Analysis of timing (immediate vs. delayed) and frequency of RIPC.
• Focus on human experimental models with controlled confounding factors.

Main Results:

• Repeated RIPC bouts over days uniquely improve vascular function compared to single bouts.
• Changes in resistance vessel and microvascular function are key indicators.
• RIPC's protective effects are influenced by timing and frequency.

Conclusions:

• Repeated RIPC may offer benefits beyond single-bout interventions.
• RIPC's potential as a preclinical strategy to delay cardiovascular disease progression is highlighted.
• Further research in controlled human models is needed to optimize RIPC protocols.